Background. Many transplantation centres have switched to C2 monitoring of cyclosporin-treated renal transplant patients. The rationale is that the C2 correlates best with AUC 0-4 (area under the concentration-time curve), which again correlates with rejection and nephrotoxicity. It has also been demonstrated that calcineurin phosphatase is inhibited maximally 1-2 h after intake of cyclosporin in patients receiving their first dose. Cyclosporin is metabolized to many compounds, which may influence the results of immunoassays. Some metabolites may have immunosuppressive activity. Methods. Cyclosporin metabolites were added to whole blood from healthy volunteers and the calcineurin phosphatase activity (CaN) was determined. Twenty renal transplant patients at varying times after transplantation had blood samples drawn in the morning before and 1, 2, 3 and 4 h after intake of their usual dose of cyclosporin microemulsion. Whole blood samples were analysed by liquid chromatography/tandem mass spectrometry for cyclosporin blood concentration and for the cyclosporin metabolites AM1, AM9, AM1c and AM4n. All samples were analysed for CaN utilizing a 32 P-labelled 19 amino-acid peptide. Results. The concentrations of AM1c and AM4n were very low and cannot contribute to CaN inhibition. The ratio of AM1 and AM9 to cyclosporin was high before intake of the drug, but it was much lower during the following 4 h. The 2-h values of cyclosporin were the best predictors of AUC 0-4 . Calcineurin phosphatase was most inhibited in the 2-h samples and the 2-h value of CaN was the best predictor of CaN AUC 0-4 . The correlation with calcineurin inhibition seemed better for cyclosporin plus metabolites than for cyclosporin. Conclusions. Samples collected at 2 h are the best predictors of AUC 0-4 for both cyclosporin and calcineurin inhibition. The impact of metabolites appears to be small; however, the temporal profile of calcineurin inhibition seemed to follow cyclosporin plus metabolites better than cyclosporin alone.
Introduction
Despite the availability of many newer immunosuppressive drugs, cyclosporin (CsA) in the microemulsion formulation still remains the cornerstone of immunosuppression after renal transplantation in many centres [1] . CsA exerts its immunosuppressive action by inhibiting calcineurin phosphatase [2] . The variable pharmacokinetics [3] and narrow therapeutic index of the drug have made therapeutic drug monitoring (TDM) necessary and many TDM strategies have been advocated for [4] . After having utilized blood CsA determinations of samples taken 12 h after oral intake (C0: trough-level monitoring), many centres have now switched to C2 monitoring (e.g. monitoring with samples drawn 2 h after oral intake of the drug). The rationale for C2 monitoring is based primarily on the observation that the greatest variability of the area under the concentration-time curve (AUC) appears within the first 4 h after oral intake of the drug, that the C2 correlates best with AUC 0-4 and that AUC 0-4 correlates well with both rejection and nephrotoxicity [5, 6] . Investigations with polyclonal and monoclonal antibodies for the determination of CsA indicate that the relative amount of CsA metabolites is greater at C0 than at C2 [7] . Depending on the immunosuppressive activity of the metabolites, this could favour either C0 or C2 monitoring. In patients receiving a single dose of CsA, it has been demonstrated that the calcineurin phosphatase activity (CaN) is inhibited maximally 2 h after intake of the drug [8] . The aim of the present investigation was to define the impact of active CsA metabolites on C2 and C0 monitoring.
Subjects and methods
The study was approved by the local ethics committee (Den videnskabsetiske Komite´for Å rhus Amt, jr. nr. 20010313) and the Danish drug authorities (Laegemiddelstyrelsen).
Patients
Twenty randomly selected renal transplant patients, 18 males and two females, were included in the study. Among them, seven were within the first year after transplantation and five were transplanted >1 year ago. The mean age was 52 years (range: 29-68 years). The immunosuppressive regimen consisted of CsA microemulsion and prednisolone for all patients. Additionally, 12 subjects received azathioprine. The mean (±SD) CsA dose was 218±82.8 mg (range: 125-350 mg) twice daily. The investigations were carried out in the morning and the patients were not fasting. Blood samples were drawn before and 1, 2, 3 and 4 h after oral intake of their usual dose of CsA. Samples were collected into tubes containing EDTA and frozen at À80 C until analysis for calcineurin activity, CsA and metabolites was performed, within a maximum of a 2 week period.
CaN assay
CaN was determined utilizing an assay described in detail previously [9] . Briefly, CaN activity was measured by its ability to dephosphorylate a 19 amino-acid peptide previously phosphorylated with g-32 P-ATP. Radioactivity was counted using liquid scintillation and results converted from counts per min to units CaN. The results are given as units of bovine calcineurin per 40 ml EDTA blood.
Drug and metabolite determinations
CsA and metabolites were determined by liquid chromatography/tandem mass spectrometry (LC/MSMS). Samples for standards were generously supplied by Novartis (Basel, Switzerland). Of the numerous CsA metabolites present in blood, only AM1 and AM9 have been found in immunosuppressive significant amounts, as determined by the mixed lymphocyte culture assay [10] . We, therefore, determined the hydroxylated metabolites AM1 and AM9 but also AM1c as a cyclic metabolite and AM4n as a demethylated metabolite.
'Ex vivo' experiments
In some preliminary ex vivo experiments, 5 ml of solutions of CsA or metabolites in ethanol, Tween and NaCl-Tris buffer were added to 495 ml EDTA blood from a healthy volunteer to a final concentration of 10, 5, 2 and 1 mM, followed by calcineurin activity determination. These experiments showed no inhibition by AM1c, as could be expected since cyclated metabolites show no affinity for cyclophilin. The inhibition by the other metabolites at 10 mM was less than that at 1 mM CsA. The inhibitions by CsA concentrations >2 mM were essentially the same. In a new set of experiments, 5 ml of solutions of CsA at 1 mM and AM1, AM9 and AM4n at 10 mM were added to blood from five healthy volunteers. Inhibition of calcineurin activity was determined compared with 10 mM CsA defined as 100% inhibition and ethanol, Tween and NaCl-Tris buffer solution defined as 0% inhibition.
Statistical analysis
AUC 0-4 was determined utilizing the trapezoidal rule. Comparisons of differences in values at different times after drug intake were made by the paired Student's t-test. Correlations were investigated using Pearson's test. The significance level was set at 0.05.
Results
The results of the 'ex vivo' experiments demonstrated that the inhibition by 10 mM AM1, AM9 and AM4n did not exceed that by 1 mM CsA (Table 1) . We, therefore, conclude that the calcineurin phosphataseinhibiting activity of these metabolites is <10% of that of CsA.
Results are shown in Tables 2-4 and Figure 1 . The CsA concentrations at 1 and 2 h were not significantly different, while paired comparisons of values obtained at all other time points were significantly different. This was also the case for the sum of CsA and metabolites. As illustrated in Figure 1 , the CsA concentration peaked within 1-2 h and then decreased gradually. The CaN was significantly inhibited during the 4 h observation period compared with pre-dose levels. The maximum inhibition was 61.9±15.4% (range: 26.3-86.8%) of the pre-dose activity achieved 2 h post-dose. Thereafter, the enzyme activity increased gradually and at the 4 h time-point the levels were statistically significantly higher than the 2 h CaN activity.
Parent drug and metabolite concentrations are displayed in Table 2 . The metabolite concentrations were significantly increased at 1, 2, 3 and 4 h compared with pre-dose levels. AM1, AM9 and AM1c reached their peak level after 2 h and remained at this high level afterwards. AM4n showed a maximum at 2 h and a decrease thereafter. As could be expected, (Table 3) . The correlation coefficients depicted in Table 4 confirm that the 2-h values correlate best with AUC 0-4 for both CsA and CaN inhibition. Although the correlation between all CsA values and CaN values was highly significant (P<0.005), it was poor with a correlation coefficient of À0.35. The correlation coefficient between mean CaN activity at the different time-points and mean CsA concentration at the different time-points was À0.81. The similar correlation coefficient between mean CaN activity and mean AM1 concentrations was À0.90, the same as for AM9, while the correlation coefficient between mean CaN activity and mean of the sum of CsA and metabolite concentration was À0.96. There was no significant correlation between CsA at any time point and AUC 0-4 of CaN. The correlations between the AUC 0-4 of the metabolites and AUC 0-4 of CaN were poor. Pearson's correlations were À0.21 for CsA, À0.16 for AM1, À0.34 for AM9 and À0.26 for the sum of CsA and metabolites.
Discussion
We have confirmed the significance of the 2-h CsA whole blood concentration as the best predictor of the AUC 0-4 . We have demonstrated that the relative influence of metabolites on calcineurin inhibition would be greatest before (or 12 h after) oral intake of CsA, since the relative proportion of metabolites is largest at this time point. Different immunoassays for determining CsA concentrations display variable specificities for the parent drug and metabolites [7, [10] [11] [12] . At pre-dose levels, the amount of metabolites is more than double (235%) the concentration of CsA (Table 3) . Given the relatively small calcineurininhibiting capacity of the metabolites, assays that also determine metabolites will greatly overestimate the pharmacological effect of the drug at pre-dose level. In contrast, very specific assays will only underestimate this effect to a very small degree. At C2 this discrepancy will be minimized, since the relative concentration of metabolites is much smaller. Consequently, we conclude that C2 monitoring is more assay-independent compared with C0. This is in agreement with previously published results [13] .
In CsA-treated patients we have found a rapid decline in CaN after oral intake of the drug. CaN was inhibited maximally in samples 2 and 3 h post-dose. Halloran et al. [8] investigated, among others, a group of CsA-treated patients taking their first dose of the drug. They observed the maximal CaN inhibition 1-2 h following drug intake. This conclusion supports the Table 2 . Mean (SE) blood concentration of CsA (ng/ml), CsA metabolites (ng/ml) and calcineurin activity (units/40 ml blood) before and 1, 2, 3 and 4 h after oral intake of CsA microemulsion in 20 renal transplant patients All: sum of AM1, AM9, AM1c and AM4n. rationale of the C2 monitoring [14] . Furthermore, we demonstrated that the 2-h CaN was the best predictor of CaN AUC 0-4 . We did find a significant but poor correlation between the CsA and CaN values. This is similar to what we have demonstrated in patients treated with tacrolimus [9] . Among the possible explanations could be that some patients have very low CaN values at C0. Therefore, their CaN values cannot be expected to be able to decrease further, while the CsA values, naturally, will increase. Additionally, it seems that the blood concentration required to produce a given inhibition exhibits great variation among patients. Finally, variation introduced by the assay itself could add to this observation.
The mean drug concentrations at every time-point displayed good correlations with the corresponding CaN. This correlation was best for the sum of CsA and metabolites. As we have demonstrated, CsA metabolites displayed low inhibitory activity on CaN. Therefore, metabolite inhibition could not reasonably explain these results. There may be a time delay in the enzyme gaining its activity compared with the blood CsA concentration, so it parallels the sum of CsA and metabolites better than CsA. This could favour TDM with unspecific CsA assays that also measure metabolites.
This seems to be in contrast to tacrolimus, where we have previously reported [8] that CaN increased faster than blood tacrolimus concentrations declined.
We were unable to demonstrate any significant correlation between CsA determinations at any time point and CaN AUC 0-4 .
In conclusion, we have demonstrated that the CsA metabolites play a limited role in CaN inhibition. This seems to favour the usage of specific assays for CsA drug determinations. On the other hand, we found a temporal profile of CaN inhibition that may favour unspecific assays which additionally determine metabolites.
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